engraftment after high-dose chemotherapy compared to autologous BM. Allogeneic transplants with PBSC have also been shown to provide hastened tri-lineage Growth factor administration to donors prior to bone marrow (BM) harvesting results in an enrichment of the engraftment. 1,2 However, there is a growing concern that unmanipulated allogeneic PBSC transplants may lead to a graft for myeloid precursors. In animals, growth factorprimed BM has a higher repopulating ability than higher incidence of graft-versus-host disease (GVHD) especially of chronic extensive GVHD. 3 Intriguingly, the untreated BM. Ten patients received an HLA-identical sibling, allogeneic transplant using granulocyte colonyincidence of GVHD after allogeneic PBSC transplantation seems not to correlate with the number of T lymphocytes stimulating factor (G-CSF)-stimulated BM. Stimulation consisted of G-CSF at 10 g/kg/day for 2 days prior to infused. 3 Furthermore, positive CD34 + cell selection of PBSC with concurrent depletion of T lymphocytes does not harvest. Patients were transplanted for various benign and malignant hematological conditions. The GVHD seem sufficient to eliminate GVHD. Whether the G-CSF PBSC mobilization schedules currently in use result in simultaneous enrichengraftment of white cells and platelets. On average they attained an ANC of у1 ؋10 9 /l 9 days earlier and ment of the stem cell and progenitor content of the BM, or simply in a shift of these cells from the BM to the peria platelet count of у20 ؋ 10 9 /l 6 days earlier than historical controls receiving unstimulated HLA-identical pheral blood, has not been elucidated. A small number of studies has been conducted to detersibling BM. Hospitalization was shortened by a mean of 10 days and transfusion requirements were modest. mine the progenitor content and engraftment capability of growth factor-stimulated BM. In mice, G-CSF and stem None of the patients developed severe GVHD or disease relapse. Two patients died of severe VOD post-BMT cell factor produce 10-fold or greater increase in the BM repopulating ability in competitive assays. 10 In human studand thus were unevaluable for platelet engraftment. A third patient died of TTP on day 76 post-BMT. Seven ies, an increased number of committed myeloid progenitors 11 and CD34 + cells 12 were documented in BM harvests patients are alive and well 49-585 days post-BMT. Stimulated BM may provide a valuable alternative to from stimulated donors. Two studies using interleukin-3 and G-CSF 13 or GM-CSF 14 -stimulated BM failed to show allogeneic BM and PBSC transplants. Ideal stimulation regimens need to be investigated.
The administration of G-CSF to normal donors is now prophylaxis consisted of cyclosporine, methotrexate and/or prednisone. Compared to untreated historical routinely used for the collection of PBSC for autologous transplant and, with increasing frequency, for collection of control BM, stimulated BM infusions contained similar number of nucleated cells (mean ؎ s.d.: 3.5 ؎ 1.5 vs PBSC for syngeneic and allogeneic transplantation. uals has been recently published by Anderlini et al. 8 In normal individuals a short course of G-CSF leads to rapid 129 ؎ 30 vs 190 ؎ 59 ؋ 10 6 /kg) but higher numbers of granulocyte-macrophage colony-forming units expansion of the cellularity of the BM and the appearance of both committed and primitive progenitors in circulating (mean ؎ s.d.: 20 ؎ 12 vs 96 ؎ 34 ؋ 10 4 /kg). Patients receiving stimulated BM had prompt and stable peripheral blood. 9 Whether the G-CSF PBSC mobilization schedules currently in use result in simultaneous enrichengraftment of white cells and platelets. On average they attained an ANC of у1 ؋10 9 /l 9 days earlier and ment of the stem cell and progenitor content of the BM, or simply in a shift of these cells from the BM to the peria platelet count of у20 ؋ 10 9 /l 6 days earlier than historical controls receiving unstimulated HLA-identical pheral blood, has not been elucidated. A small number of studies has been conducted to detersibling BM. Hospitalization was shortened by a mean of 10 days and transfusion requirements were modest. mine the progenitor content and engraftment capability of growth factor-stimulated BM. In mice, G-CSF and stem None of the patients developed severe GVHD or disease relapse. Two patients died of severe VOD post-BMT cell factor produce 10-fold or greater increase in the BM repopulating ability in competitive assays. 10 In human studand thus were unevaluable for platelet engraftment. A third patient died of TTP on day 76 post-BMT. Seven ies, an increased number of committed myeloid progenitors 11 and CD34 + cells 12 were documented in BM harvests patients are alive and well 49-585 days post-BMT. Stimulated BM may provide a valuable alternative to from stimulated donors. Two studies using interleukin-3 and G-CSF 13 or GM-CSF 14 -stimulated BM failed to show allogeneic BM and PBSC transplants. Ideal stimulation regimens need to be investigated.
faster engraftment compared to unstimulated BM but a third study using G-CSF showed hastened engraftment.
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Keywords: filgrastim; growth factor mobilization; engraftment; GVHD We initiated a pilot study to assess engraftment and GVHD after BMT using G-CSF stimulated donors. forming unit granulocyte-macrophage (CFU-GM) content GVHD prophylaxis consisted of cyclosporin A (CsA) was determined using a semi-solid agar assay described 1.5 mg/kg i.v. every 12 h starting on day −1 and methotrexelsewhere 17 scored as colonies/10 6 cells plated and reported ate (MTX) 15 mg/m 2 i.v. on day 1 and 10 mg/m 2 on days as CFU-GM dose/kg recipient body weight. Historical 3, 6 and 11. Intravenous gamma globulin (IVgG) 0.5 g/kg controls were 112 recipients of BM from HLA-identical was given every 2 weeks starting day 1. MTX was held if siblings harvested at our center. the total serum bilirubin concentration was Ͼ2 mg/dl. Patients who did not receive MTX were given solumedrol Statistics 0.5 mg/kg/day i.v. on days 7-14 and 0.5 mg/kg twice a day i.v. on days 14-28. Upon discharge patients treated with
Because of the limited number of patients only descriptive solumedrol received prednisone. Prednisone was tapered statistics are used. according to the following schedule: 0.8 mg/kg/day days 29-43, 0.5 mg/kg/day days 44-56, 0.2 mg/kg/day days 57-119 and 0.1 mg/kg/day days 120-179.
Results Supportive care included gut decontamination, sterile LAF isolation, fluconazole, high-dose i.v. acyclovir and PCP prophylaxis. Patients with diagnosis other than AML Patients and conditioning or CML received G-CSF or GM-CSF starting on day 0.
Patient characteristics are summarized in Table 1 . Eight Prophylactic transfusions of platelets were given for a platpatients were male and two female. The mean age was 33 elet count of р10 × 10 9 /l if not bleeding and р50 × 10 9 /l (range 15-56). Four patients had CML; one was Ph − and if bleeding occurred. BCR − ABL − but had a t(5;12) and the others had Ph + . One Times to ANC Ͼ0.5 × 10 9 /l and 1 × 10 9 /l were the first patient had a trisomy 8 in addition to Ph + . The other of 3 consecutive days with those neutrophil counts. Times patients had refractory NHL (two), Waldenström's disease to platelet counts Ͼ20 × 10 9 /l were the first of 3 days with (one), severe aplastic anemia (SAA) (two) and biphenosuch platelet count, after 1 week without platelet transtypic leukemia (one). All patients were genotypically identfusions. Donor hematopoiesis was determined by standard ical with their sibling donors at the HLA class I and II loci cytogenetics and/or fluorescence in situ hybridization as assigned by family studies. Five had sex matched and (FISH) analysis using a BCR-ABL and/or a dual XY probe.
five sex mismatched donors. Two female donors had prior The length of stay included hospitalization during the pregnancies. Four patients received GVHD prophylaxis conditioning regimen. GVHD was ascertained clinically with CSA/MTX while six received CSA/PRD. using a standard GVHD grading scale. 16 Historical controls consisted of 112 patients who received whole, unstimulated HLA-identical allogeneic BM transplants at our center. For length of stay only 23 patients undergoing matched related (36 ± 10 days) compared to BM (46 ± 15 days).
Outcome Cell and progenitor contents
All patients demonstrated complete donor hematopoietic reconstitution at the time of discharge or death and at last The cell content of stimulated and unstimulated grafts is follow-up. Seven patients are alive and disease free at 585, shown in Table 2 failures were observed. None of the patients had clinical The CFU-GM/kg recipient body weight was higher in evidence of severe (grade III or IV) skin, intestine or liver stimulated harvests (96 ± 34 × 10 4 /kg vs 20 ± 12 × 10 4 /kg) GVHD. Grade I-II GVHD of the skin was present in three (Table 2) .
patients (Table 5) .
Engraftment Donor tolerance for mobilization regimen Engraftment and transfusional requirement data are shown
All donors completed the mobilization regimen. No dose in Table 3 . Rapid and stable neutrophil engraftment was required a dose reduction of G-CSF. All donors reported observed in all patients. Two patients (Nos 254 and 304) moderate bone pain prior to harvesting. Three of the donors died on day 48 and 91 post-BMT due to severe VOD. Plateused acetaminophen on the second day of G-CSF adminislet engraftment data are not available in these patients since tration. platelet transfusions were given to maintain a platelet count of Ͼ50 × 10 9 /l while the patients received heparin and tissue plasminogen activator. The median day to Discussion ANC Ͼ0.5 × 10 9 /l was 14 days (range 17-25) while the median engraftment time for platelets Ͼ20 × 10 9 /l in the This pilot study shows that a short course of G-CSF given eight evaluable patients was 20 days (range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] to donors prior to harvest is well tolerated. This resulted in (Table 3) . Hospitalization discharge ranged from 22 to 34 minimal changes in CD34 + and CD3 + cell content of the days post-transplant for the six patients discharged. Except graft while increasing the number of committed progenitors for the patients who experienced fatal VOD, the other as measured in the CFU-GM assay. While flow cytometry analyses of CD34 + and CD3 + cell content and CFU assays Alive, NED, day 49 --Donor hematopoiesis NED = no evidence of disease; TTP = thombotic thrombocytopenia purpura; VOD = veno-occlusive disease; IP = interstitial pneumonitis.
Transplantation with stimulated BM resulted in rapid and days to donor mice reduced the severity of GVHD and increased survival in an experimental mismatched mouse stable engraftment. No severe GVHD was seen. In four patients who received MTX, engraftment of granulocytes BMT model. 20 Animal studies and our data suggest that the use of Gand platelets took longer. It is thus possible that the differences between stimulated BM and unstimulated BM are in CSF-stimulated BM may provide engraftment and incidence of acute GVHD rates at least comparable, and perpart due to differing GVHD prophylaxis. Alternatively, it is possible that MTX, by preferential cytotoxicity of actively haps superior, to unmanipulated BM. The presence of higher numbers of committed progenitors correlated with proliferating myeloid progenitors blunted the advantage of stimulated BM on engraftment. A modest effect on relatively rapid engraftment, shorter hospital stays and lower transfusion requirements. The potential concern of engraftment may also be accounted for by the administration of growth factors in patients 214, 254, 265 and 314.
loss of stem cells by differentiation or mobilization into peripheral blood secondary to the administration of growth However, rapid neutrophil engraftment was verified in two patients who did not receive post-BMT growth factor. factor resulting in graft failure was not verified in our study. Further studies to determine the optimal schema for stimuLonger schedules of G-CSF stimulation may be needed to see a more profound effect on engraftment and these studies lation of BM and the incidence of GVHD and leukemic recurrence are warranted. are ongoing. Because sampling BM serially in normal volunteers is impractical, using cohorts of donors stimulated with escalating doses of G-CSF may represent the only way to define the optimal BM stimulation schema. 
